Like many, I read the Biotech Stock Mailbag article this morning. The glaring thing is that Mr. Feuerstein (AF) leaves out an entire history for Aethlon which involves years of interaction with numerous governmental and health agencies which one assumes are pretty well positioned to understand the value Aethlon brings to the table. Please read the piece I wrote on this blog yesterday for a little more background or just do a little due diligence on your own and make your own decisions. The article today does not mention the current contract with DARPA (an agency of the Department of Defense) which requires that underlying research hurdles be met and is renewed annually; does not mention the results presented by Dr. Helmut Geiger of Frankfurt University Hospital in Philadelphia in the wake of the successful treatment of Dr. Mawanda and paints a broad brush in stating that any trial results out of India, even at a medical center considered to be one of India’s best, are somehow suspect even though there seems little evidence to support that claim in this case.
I had seen a reply from the same Nebraska Medical spokesperson in a post on Investors Hub prior to Dr. Salia’s death which stated that he was aware of the Hemopurifier and that it “might” yet be used. We know now they didn’t use it but we also know the patient died. If you are going to slam a company for trying to offer up its product in that situation or in preparation for future events like it you have to ask yourself the following:
What moronic company would try to push their product on someone in that situation if they believed it didn’t work? Who would send their product to be used on someone with likely near total organ failure, unconscious and damn close to their last breath? That seems like a sure fire way to have your product be deemed a failure if he dies right? The fact that the company has been willing to risk its reputation and its very future by taking that big a risk, the same risk they saw fit to take in Frankfurt Germany with Dr. Mawanda, is one of the underlying reasons I have been so bullish on this stock and this technology.
We do expect that Aethlon will give investors more insight into its next steps and plans for commercialization. One big step in that direction is the upcoming FDA study that will kick off at the DaVita MedCenter in Houston. The Street piece does not mention this study (or anything about the FDA clearances Aethlon has been given) which seems a pretty big oversight.